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Regarding “Intraoperative use of dextran is associated
with cardiac complications after carotid
endarterectomy”
We read with great interest the recent article by Farber et al1
on behalf of the Vascular Study Group of New England regarding
the high cardiovascular complication rate associated with the use
of dextran as an antithrombotic agent after carotid endarterec-
tomy (CEA). The strongest evidence to support intravenous
dextran after CEA is based on its selective use when patients
have persistently high transcranial Doppler (TCD)-detected
microembolization.2Fig. Microemboli signals (MES) after carotid endarterectomy in
patients on single-antiplatelet therapy before surgery.C, Dextran-
40 (n ¼ 28); B, patients (n ¼ 4) who developed early stroke,
despite dextran-40 infusion; -, tiroﬁban (n ¼ 32); :, no addi-
tional antiplatelet treatment (n ¼ 36).6 Reproduced with permis-
sion from Saedon et al.6Cerebral microemboli appear to be primarily solid platelet
aggregates. Microemboli are associated with a high risk of subse-
quent stroke and can be successfully controlled with a number of
antiplatelet agents, including aspirin, dextran, and S-nitrosogluta-
thione.3 We found that it was possible to control microemboli in
patients with recurrent or crescendo transient ischemic attacks
using preoperative TCD-directed dextran therapy, and so safely
defer CEA until the next elective list.4 However in this small
cohort, the cardiovascular side effects of dextran appeared exces-
sive. We therefore attempted to use a more selective TCD-
directed intravenous antiplatelet agent, a glycoprotein IIb/IIIa
receptor antagonist (tiroﬁban), to control transient cerebral
microemboli both before and after CEA.5 In view of our
previous experience of the effectiveness and tolerability of the
intravenous glycoprotein IIb/IIIa antagonist antiplatelet agent
(tiroﬁban),5 we have recently compared the efﬁcacy of dextran
with tiroﬁban and found that TCD-directed tiroﬁban therapy
appears more effective than dextran-40 in suppression of cerebral
microemboli after CEA, with a lower side effect proﬁle6 (Fig).
Our ﬁndings support the authors’ conclusions that dextran
has a limited role in carotid endarterectomy. In our opinion,
TCD-directed tiroﬁban would be a safer and more efﬁcacious
approach to reduce stroke risk after carotid endarterectomy in
these patients.Christopher Imray, PhD, FRCS, FRCP, FRGS
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Reply
Multiple studies have demonstrated the efﬁcacy of transcranial
Doppler (TCD)-directed dextran therapy during carotid endarter-
ectomy (CEA).1-3 In our recent review of 6641 CEAs performed
within the auspices of the Vascular Study Group of New England,4
we found perioperative infusion of dextran was not correlated with
lower stroke rates but rather was associated with increased postop-
erative cardiac complications, including myocardial infarction and
congestive heart failure. We concluded that there was limited clin-
ical utility for the routine use of dextran during CEA.
We read with great interest the article by Saedon et al5
regarding the efﬁcacy of TCD- directed antiplatelet therapy during
CEA. These authors found TCD-directed infusion of the glyco-
protein IIb/IIIa antagonist tiroﬁban was more effective than
dextran in reducing transient cerebral microemboli before and
after CEA.5 Their conclusions suggest a potential role of TCD-
directed tiroﬁban infusion during CEA. Although these ﬁndings
are provocative, widespread use of tiroﬁban cannot be recommen-
ded from on these data alone. Further investigation of this agent in
CEA patients is warranted.
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